Articles from Wyss Institute at Harvard University

Wyss Institute Technologies Enable Breakthrough in Astronaut Health Research Aboard NASA’s Artemis II Mission
Wyss Institute-enabled Organ Chip “avatars” will provide insights into astronaut health risks and provide a tool for future discovery of countermeasures necessary for travel to the Moon and beyond
Wyss Institute-led collaboration awarded by ARPA-H PRINT program to engineer off-the-shelf, universal, transplant-ready graft for liver failure
Highly multidisciplinary, multi-institutional team of world-leading experts to build technological foundation for liver transplants that could save thousands of patients
Wyss Institute at Harvard University appoints three new Associate Faculty members: Ahmad Khalil, Jarad Mason, and Ting Wu
These three distinguished researchers bring their expertise in synthetic biology, materials science, and genome research to contribute to the Institute’s mission of societal impact
Wyss Institute at Harvard University Announces Appointment of Natalie Artzi, Ph.D., to Associate Institute Director
Dr. Artzi will work closely with the Wyss Founding Director Don Ingber and the Wyss executive and senior leadership teams in shaping the strategic direction of the Institute
Wyss Institute Launches Healthy Aging Fund with a Gift from The Colossal Foundation
The Healthy Aging Fund will explore the intricate connection between human and planetary health, aiming to unlock the secrets of aging and extend lifespans
Wyss Institute Research Collaboration Awarded ARPA-H Agreement to Develop Disease-Agnostic Immunotherapeutic RNA Platform
Multidisciplinary project aims to advance novel RNA immunotherapeutic in combination with innovative delivery systems to broadly boost anti-tumor and -pathogen immunity in a range of patient settings.
Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies
The company is developing the biomaterial-based technology to develop novel therapies able to program anti-cancer immunity and prevent infectious diseases
Circe Bioscience licenses technology to decarbonize industry with microbes developed at Wyss Institute at Harvard University
Novel gas fermentation approach enables engineered microbes to eat greenhouse gases and produce valuable products for multiple uses
Wyss Institute’s AminoX project receives funding from Northpond Labs to accelerate innovation in protein-based therapeutics
Northpond-funded Laboratory for Bioengineering Research and Innovation makes its fourth investment into the future of biotech
Harvard’s Wyss Institute and Collaborative Fund cofound research lab to fund technology to combat climate change
Collaborative Fund commits $15 million to create a Laboratory for Sustainable Materials Research and Innovation at the Wyss Institute
Wyss Institute’s Lab-on-a-Molecule Drug Discovery Project Receives Funding from Northpond Labs
Laboratory for Bioengineering Research and Innovation, funded by Northpond Labs, supports third Wyss Institute project on a path toward commercialization
Gameto licenses Wyss Institute’s technology for growing human ovaries from Harvard University
First fully human ovarian organoids could be used to develop new treatments for women’s reproductive health
Wyss Institute at Harvard University partners with Northpond Labs to launch RNA solutions company EnPlusOne Biosciences
Startup aims to bring a versatile, sustainable, and scalable RNA synthesis technology to market to unlock development of new RNA drugs, vaccines, and gene-editing therapies
Sherlock Biosciences licenses Wyss Institute’s ambient nucleic acid amplification technology from Harvard to develop highly accurate, low-cost diagnostics for point-of-need
The method, integrated with highly specific CRISPR-based nucleic acid detection technology, could enable simple-to-use, portable and ultra-sensitive diagnostics for infectious disease detection in low-resource settings
Unravel Biosciences licenses Wyss Institute platform technology from Harvard and Tufts University to decode, model, and treat complex diseases
The company is developing therapeutics for rare genetic diseases affecting the central nervous system, starting with Rett syndrome
By Wyss Institute at Harvard University · Via GlobeNewswire · September 27, 2022